Exploring the neuromagnetic signatures of cognitive decline from mild cognitive impairment to Alzheimer's disease dementia
- PMID: 40153923
- PMCID: PMC11995804
- DOI: 10.1016/j.ebiom.2025.105659
Exploring the neuromagnetic signatures of cognitive decline from mild cognitive impairment to Alzheimer's disease dementia
Abstract
Background: Developing non-invasive and affordable biomarkers to detect Alzheimer's disease (AD) at a prodromal stage is essential, particularly in the context of new disease-modifying therapies. Mild cognitive impairment (MCI) is a critical stage preceding dementia, but not all patients with MCI will progress to AD. This study explores the potential of magnetoencephalography (MEG) to predict cognitive decline from MCI to AD dementia.
Methods: We analysed resting-state MEG data from the BioFIND dataset including 117 patients with MCI among whom 64 developed AD dementia (AD progression), while 53 remained cognitively stable (stable MCI), using spectral analysis. Logistic regression models estimated the additive explanation of selected clinical, MEG, and MRI variables for AD progression risk. We then built a high-dimensional classification model to combine all modalities and variables of interest.
Findings: MEG 16-38Hz spectral power, particularly over parieto-occipital magnetometers, was significantly reduced in the AD progression group. In logistic regression models, decreased MEG 16-38Hz spectral power and reduced hippocampal volume/total grey matter ratio on MRI were independently linked to higher AD progression risk. The data-driven classification model confirmed, among other factors, the complementary information of MEG covariance (AUC = 0.74, SD = 0.13) and MRI cortical volumes (AUC = 0.77, SD = 0.14) to predict AD progression. Combining all inputs led to markedly improved classification scores (AUC = 0.81, SD = 0.12).
Interpretation: These findings highlight the potential of spectral power and covariance as robust non-invasive electrophysiological biomarkers to predict AD progression, complementing other diagnostic measures, including cognitive scores and MRI.
Funding: This work was supported by: Fondation pour la Recherche Médicale (grant FDM202106013579).
Keywords: Alzheimer's disease (AD); Brain rhythms; Disease progression; Magnetoencephalography (MEG); Mild cognitive impairment (MCI); Spectral power.
Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of interests C.P. received payment or honoraria for advisory board from Lilly, Roche and Eisai. C.P. also received payments for consultation on the advisory boards of Lilly, Roche, Eisai and Novo Nordisk. C.P. received support for attending meetings, travel from Lilly, Roche and Eisai. P.G., J.F.H. & D.E. are full-time employees of F. Hoffmann–La Roche Ltd. F.M. received a grant from the Ministry of Science Government of Spain (grant PID2021-122979OB-C21).
Figures





References
-
- Alzheimer’s Association 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19:1598–1695. - PubMed
-
- Hampel H., Lista S. Dementia: the rising global tide of cognitive impairment. Nat Rev Neurol. 2016;12:131–132. - PubMed
-
- Van Dyck C.H., Swanson C.J., Aisen P., et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388:9–21. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources